✦ LIBER ✦

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

✍ Scribed by Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato

Book ID: 117785110
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 163 KB
Volume: 10
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(09)70232-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Olanzapine for the Prevention of Chemoth

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study

✍ Mizukami, Naomi; Yamauchi, Masanori; Koike, Kazuhiko; Watanabe, Akihiko; Ichihar 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 243 KB

Double-blind, placebo-controlled cross-o

Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer

✍ A Awidi; U Homsi; R.I Kakail; A Mubarak; A Hassan; M Kelta; P Martinez; S Sulait 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

Intravenous aflibercept for treatment of

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Walter H Gotlieb; Frederic Amant; Suresh Advani; Chanchal Goswami; Hal Hirte; Di 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 196 KB

A randomized, placebo-controlled, double

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen

✍ Paul Ruff; D. A. Vorobiof; J. P. Jordaan; G. S. Demetriou; S. D. Moodley; A. L. 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 225 KB

8LBA Biomarker evaluation in the randomi

8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

✍ B. Johnson; V. Miller; L. Amler; H. Stern; C. Soh; P. O'Connor; F. Kabbinavar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB